Self-Study 2024 Release I: PARP Inhibitor Combination Regimens for mCRPC
In 2023, the FDA approved three combination regimens of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors plus novel hormonal therapy (NHT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with certain homologous recombination repair (HRR) alterations. These combination regimens include olaparib with abiraterone/prednisone, talazoparib with enzalutamide, and niraparib with abiraterone/prednisone. In this module, participants will evaluate the phase III trials that investigated the use of these PARP inhibitor containing combination regimens for the treatment of mCRPC, along with considerations associated with these new regimens.
Course Information
PARP Inhibitor Combination Regimens for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
UAN# 0465-0000-24-073-H01-P
Author: Bryan Fitzgerald, PharmD, BCOP
Learning Objectives
- Recognize the safety considerations of current PARP inhibitor + novel hormonal therapy combination regimens in the treatment of mCRPC
- Identify the most appropriate patient populations where combination PARP inhibitor + novel hormonal therapy regimens have shown clinical benefit
- Evaluate primary literature supporting the use of these combination regimens
- Develop appropriate treatment and supportive care plans utilizing PARP inhibitor combination therapy for patients with mCRPC with homologous recombination repair (HRR) gene alterations
Get it
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.